Daily Stock Analysis, JAGX, Jaguar Health Inc, priceseries

Jaguar Health Inc. Daily Stock Analysis
Stock Information
Open
0.23
Close
0.24
High
0.24
Low
0.23
Previous Close
0.24
Daily Price Gain
0.00
YTD High
0.39
YTD High Date
Jan 7, 2019
YTD Low
0.22
YTD Low Date
Jan 2, 2019
YTD Price Change
-0.03
YTD Gain
-11.11%
52 Week High
6.60
52 Week High Date
Mar 8, 2018
52 Week Low
0.12
52 Week Low Date
Dec 24, 2018
52 Week Price Change
-1.84
52 Week Gain
-88.44%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 17. 2017
14.40
Mar 7. 2017
16.04
11 Trading Days
11.37%
Link
LONG
Jul 13. 2017
8.39
Jul 26. 2017
9.60
9 Trading Days
14.46%
Link
LONG
Nov 13. 2017
3.19
Nov 14. 2017
3.43
1 Trading Days
7.57%
Link
LONG
Jan 16. 2018
2.10
Jan 23. 2018
2.22
5 Trading Days
5.71%
Link
LONG
Feb 2. 2018
2.22
Feb 6. 2018
2.48
2 Trading Days
11.82%
Link
Company Information
Stock Symbol
JAGX
Exchange
NasdaqCM
Company URL
http://www.jaguaranimalhealth.com
Company Phone
415-896-5081
CEO
Lisa A. Conte
Headquarters
California
Business Address
201 MISSION STREET, SUITE 2375, SAN FRANCISCO, CA 94105
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001585608
About

Jaguar Animal Health, Inc. engages in the development and commercialization of gastrointestinal products for companion and production animals. Its product, Canalevia, is the company's prescription drug product candidate for the treatment of various forms diarrhea in dogs. It also developed its non-prescription product, Neonorm Calf, which helps dairies and beef farms proactively retain fluid in calves. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Description

Jaguar Animal Health, Inc., an animal health company, focuses on developing and commercializing gastrointestinal products for companion and production animals, foals, and high value horses. The company's lead prescription drug product candidate includes Canalevia, a canine-specific formulation of Crofelemer for the treatment of chemotherapy-induced diarrhea and acute watery diarrhea in dogs. It is also developing Crofelemer to treat acute colitis in horses and acute watery diarrhea in cats; Neonorm, an enteric-coated tablet for scours in preweaned dairy calves, as well as other animal species, such as horses, goats, and sheep; and other product candidates, including Virend for feline herpes and NP-500 for Type II diabetes and metabolic syndrome. The company was founded in 2013 and is headquartered in San Francisco, California.